Crane CR 深 滬
已收盤 10-16 16:00:00 美东时间
205.83
+0.100
+0.05%
華盛通- 最 高209.00
- 今 開205.94
- 成交量 32.02万股
- 最 低 204.075
- 昨 收 205.73
- 總市值 118.97亿
- 52周最高 230.245
- 市盈率 靜 32.90
- 換手率 0.55%
- 52周最低 159.07
- 委 比 11.11%
- 總股本 5780.04万
- 歷史最高 230.245
- 量 比 1.36
- 振 幅 2.39%
- 歷史最低 30.185
- 每 手 1
- 風險率 15.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Crane Co收涨0.05%，成交额5569.09万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 04:52
Here’s How Much You Would Have Made Owning Crane Stock In The Last 5 Years
Crane (NYSE:CR) has outperformed the market over the past 5 years by 27.95% on an annualized basis producing an average annual return of 39.28%. Currently, Crane has a market capitalization of $11.81 billion. Buying $1000 In CR: If an investor had bought $1000 of CR stock 5 years ago, it would be wo...
10-15 00:15
Full Transcript: Crane NXT Q2 2026 Earnings Call
Crane NXT (NYSE:CXT) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View t...
10-09 21:41
UBS's basket of expensive stocks faces derating risks
UBS equity strategists have constructed a 56-stock "expensive fundamentals" basket targeting companies with elevated valuations, below-average cash flow returns, and lagging growth profiles that face ...
10-08 02:18
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Kyverna Therapeutics announced positive results from its KYSA-8 trial for stiff person syndrome (SPS), showing sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS. The company also presented updated Phase 1 data for progressive multiple sclerosis (MS), highlighting encouraging clinical activity and safety. Miv-cel, a CD19-targeting CAR T-cell therapy, is being developed as a potential first-in-class trea...
10-07 12:00
Hitit Secures Five-Year Tech Deal With Ariana Afghan Airlines
Hitit Bilgisayar Hizmetleri A.S. ( ($TR:HTTBT) ) has issued an announcement. Hi...
10-06 00:18
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Kyverna Therapeutics announced positive one-year data from its Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome (SPS), showing sustained clinical benefits, including significant improvement in mobility and reduction in chronic immunotherapy use. Miv-cel demonstrated a favorable safety profile with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The company plans to include t...
09-24 10:00
Craneware Signals Transition Year After Earnings Reset
Craneware Plc (($GB:CRW)) has held its Q4 earnings call. Read on for the main h...
09-23 08:18
Crane to buy U.S. pump unit from Trillium Flow for ~$240M
Crane Company (CR) has entered into a definitive agreement to acquire the U.S. pump business of Trillium Flow Technologies for approximately $240M. The transaction is expected to close in the fourth q...
09-14 19:46
General Dynamics wins $184M Navy deal for NGEAU production
General Dynamics (GD) announced on Thursday that its Mission Systems business secured a $184.25M contract to manufacture Full Rate Production Next-Generation Electronics Attack Units (NGEAU). The cont...
09-11 05:23
公司簡介
公司名稱
|
Crane
|
行業分類
|
工业机械
|
業務描述
|
Crane Co. designs and manufactures aerospace, electronics & engineered industrial products. It operates through four segments: Aerospace & Electronics, Process Flow Technologies, Payment & Merchandising Technology, and Engineered Materials. The company was founded by Richard Teller Crane on July 4, 1855 and is headquartered in Stamford, CT.
|
Crane Co收涨0.05%，成交额5569.09万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 04:52
Here’s How Much You Would Have Made Owning Crane Stock In The Last 5 Years
Crane (NYSE:CR) has outperformed the market over the past 5 years by 27.95% on an annualized basis producing an average annual return of 39.28%. Currently, Crane has a market capitalization of $11.81 billion. Buying $1000 In CR: If an investor had bought $1000 of CR stock 5 years ago, it would be wo...
10-15 00:15
Full Transcript: Crane NXT Q2 2026 Earnings Call
Crane NXT (NYSE:CXT) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View t...
10-09 21:41
UBS's basket of expensive stocks faces derating risks
UBS equity strategists have constructed a 56-stock "expensive fundamentals" basket targeting companies with elevated valuations, below-average cash flow returns, and lagging growth profiles that face ...
10-08 02:18
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Kyverna Therapeutics announced positive results from its KYSA-8 trial for stiff person syndrome (SPS), showing sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS. The company also presented updated Phase 1 data for progressive multiple sclerosis (MS), highlighting encouraging clinical activity and safety. Miv-cel, a CD19-targeting CAR T-cell therapy, is being developed as a potential first-in-class trea...
10-07 12:00
Hitit Secures Five-Year Tech Deal With Ariana Afghan Airlines
Hitit Bilgisayar Hizmetleri A.S. ( ($TR:HTTBT) ) has issued an announcement. Hi...
10-06 00:18
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Kyverna Therapeutics announced positive one-year data from its Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome (SPS), showing sustained clinical benefits, including significant improvement in mobility and reduction in chronic immunotherapy use. Miv-cel demonstrated a favorable safety profile with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The company plans to include t...
09-24 10:00
Craneware Signals Transition Year After Earnings Reset
Craneware Plc (($GB:CRW)) has held its Q4 earnings call. Read on for the main h...
09-23 08:18
Crane to buy U.S. pump unit from Trillium Flow for ~$240M
Crane Company (CR) has entered into a definitive agreement to acquire the U.S. pump business of Trillium Flow Technologies for approximately $240M. The transaction is expected to close in the fourth q...
09-14 19:46
General Dynamics wins $184M Navy deal for NGEAU production
General Dynamics (GD) announced on Thursday that its Mission Systems business secured a $184.25M contract to manufacture Full Rate Production Next-Generation Electronics Attack Units (NGEAU). The cont...
09-11 05:23
派息除權日
|
每股總股息
| 派息日期 |
2026-08-31
|
0.25
|
2026-09-09
|
2026-05-29
|
0.25
|
2026-06-10
|
2026-02-27
|
0.25
|
2026-03-11
|
2025-11-28
|
0.23
|
2025-12-10
|
2025-08-29
|
0.23
|
2025-09-10
|
2025-05-30
|
0.23
|
2025-06-11
|
2025-02-28
|
0.23
|
2025-03-12
|
2024-11-29
|
0.20
|
2024-12-11
|
2024-08-30
|
0.20
|
2024-09-11
|
2024-05-31
|
0.20
|
2024-06-12
|
2024-02-28
|
0.20
|
2024-03-13
|
2023-11-29
|
0.18
|
2023-12-13
|
2023-08-30
|
0.18
|
2023-09-13
|
2023-05-30
|
0.18
|
2023-06-08
|
2023-02-27
|
0.47
|
2023-03-08
|
2022-11-29
|
0.47
|
2022-12-14
|
2022-08-30
|
0.47
|
2022-09-14
|
2022-05-27
|
0.47
|
2022-06-08
|
2022-02-25
|
0.47
|
2022-03-09
|
2021-11-29
|
0.43
|
2021-12-08
|
2021-08-30
|
0.43
|
2021-09-08
|
2021-05-27
|
0.43
|
2021-06-09
|
2021-02-25
|
0.43
|
2021-03-10
|
2020-11-27
|
0.43
|
2020-12-09
|
2020-08-28
|
0.43
|
2020-09-09
|
2020-05-28
|
0.43
|
2020-06-10
|
2020-02-27
|
0.43
|
2020-03-11
|
2019-11-27
|
0.39
|
2019-12-09
|
2019-08-29
|
0.39
|
2019-09-09
|
2019-05-30
|
0.39
|
2019-06-10
|
2019-02-27
|
0.39
|
2019-03-11
|
2018-11-29
|
0.35
|
2018-12-10
|
2018-08-30
|
0.35
|
2018-09-10
|
2018-05-30
|
0.35
|
2018-06-08
|
2018-02-27
|
0.35
|
2018-03-09
|
2017-11-29
|
0.33
|
2017-12-08
|
2017-08-29
|
0.33
|
2017-09-08
|
2017-05-26
|
0.33
|
2017-06-09
|
2017-02-24
|
0.33
|
2017-03-09
|
2016-11-28
|
0.33
|
2016-12-09
|
2016-08-29
|
0.33
|
2016-09-09
|
2016-05-26
|
0.33
|
2016-06-10
|
2016-02-25
|
0.33
|
2016-03-10
|
2015-11-25
|
0.33
|
2015-12-09
|
2015-08-27
|
0.33
|
2015-09-09
|
2015-05-27
|
0.33
|
2015-06-09
|
2015-02-25
|
0.33
|
2015-03-10
|
2014-11-25
|
0.33
|
2014-12-09
|
2014-08-27
|
0.33
|
2014-09-09
|
2014-05-28
|
0.30
|
2014-06-10
|
2014-02-26
|
0.30
|
2014-03-10
|
2013-11-26
|
0.30
|
2013-12-10
|
2013-08-28
|
0.30
|
2013-09-10
|
2013-05-29
|
0.28
|
2013-06-11
|
2013-02-26
|
0.28
|
2013-03-08
|
2012-11-28
|
0.28
|
2012-12-10
|
2012-08-29
|
0.28
|
2012-09-11
|
2012-05-29
|
0.26
|
2012-06-08
|
2012-02-27
|
0.26
|
2012-03-09
|
2011-11-28
|
0.26
|
2011-12-09
|
2011-08-29
|
0.26
|
2011-09-09
|
2011-05-26
|
0.23
|
2011-06-10
|
2011-02-24
|
0.23
|
2011-03-10
|
2010-11-26
|
0.23
|
2010-12-10
|
2010-08-27
|
0.23
|
2010-09-10
|
2010-05-26
|
0.20
|
2010-06-10
|
2010-02-24
|
0.20
|
2010-03-10
|
2009-11-25
|
0.20
|
2009-12-10
|
2009-08-27
|
0.20
|
2009-09-11
|
2009-05-27
|
0.20
|
2009-06-10
|
2009-02-25
|
0.20
|
2009-03-11
|
2008-11-25
|
0.20
|
2008-12-10
|
2008-08-27
|
0.20
|
2008-09-10
|
2008-05-28
|
0.18
|
2008-06-10
|
2008-02-27
|
0.18
|
2008-03-10
|
2007-11-28
|
0.18
|
2007-12-10
|
2007-08-29
|
0.18
|
2007-09-11
|
2007-05-29
|
0.15
|
2007-06-08
|
2007-02-26
|
0.15
|
2007-03-08
|
2006-11-28
|
0.15
|
2006-12-08
|
2006-08-29
|
0.15
|
2006-09-08
|
2006-05-30
|
0.13
|
2006-06-12
|
2006-02-24
|
0.13
|
2006-03-09
|
2005-11-29
|
0.13
|
2005-12-09
|
2005-08-30
|
0.13
|
2005-09-09
|
2005-05-31
|
0.10
|
2005-06-10
|
2005-02-24
|
0.10
|
2005-03-10
|
2004-11-29
|
0.10
|
2004-12-10
|
2004-08-31
|
0.10
|
2004-09-10
|
2004-06-01
|
0.10
|
2004-06-11
|
2004-03-01
|
0.10
|
2004-03-12
|
2003-12-01
|
0.10
|
2003-12-12
|
2003-08-28
|
0.10
|
2003-09-10
|
2003-05-30
|
0.10
|
2003-06-12
|
2003-02-27
|
0.10
|
2003-03-12
|
2002-11-29
|
0.10
|
2002-12-12
|
2002-08-29
|
0.10
|
2002-09-12
|
2002-05-30
|
0.10
|
2002-06-12
|
2002-02-27
|
0.10
|
2002-03-12
|
2001-11-29
|
0.10
|
2001-12-12
|
2001-08-30
|
0.10
|
2001-09-13
|
2001-05-30
|
0.10
|
2001-06-11
|
2001-02-28
|
0.10
|
2001-03-12
|
2000-11-29
|
0.10
|
2000-12-12
|
2000-08-30
|
0.10
|
2000-09-12
|
2000-05-30
|
0.10
|
2000-06-13
|
2000-03-06
|
0.10
|
2000-03-15
|
1999-12-01
|
0.10
|
1999-12-10
|
1999-09-01
|
0.10
|
1999-09-10
|
1999-06-02
|
0.10
|
1999-06-11
|
1999-03-03
|
0.10
|
1999-03-12
|
1998-12-02
|
0.10
|
1998-12-11
|
1998-08-28
|
0.15
|
1998-09-14
|
1998-06-03
|
0.13
|
1998-06-12
|
1998-03-04
|
0.13
|
1998-03-13
|
1997-12-02
|
0.13
|
1997-12-11
|
1997-09-02
|
0.13
|
1997-09-11
|
1997-06-03
|
0.13
|
1997-06-12
|
1997-03-04
|
0.13
|
1997-03-13
|
1996-12-02
|
0.19
|
1996-12-12
|
1996-09-03
|
0.19
|
1996-09-13
|
1996-06-04
|
0.19
|
1996-06-14
|
1996-03-06
|
0.19
|
1996-03-13
|
1995-12-01
|
0.19
|
1995-12-14
|
1995-09-01
|
0.19
|
1995-09-14
|
1995-05-31
|
0.19
|
1995-06-14
|
1995-03-03
|
0.19
|
1995-03-14
|
1994-11-29
|
0.19
|
1994-12-14
|
1994-08-30
|
0.19
|
1994-09-14
|
1994-05-31
|
0.19
|
1994-06-14
|
1994-03-03
|
0.19
|
1994-03-14
|
1993-11-29
|
0.19
|
1993-12-14
|
1993-08-31
|
0.19
|
1993-09-14
|
1993-05-28
|
0.19
|
1993-06-14
|
1993-03-01
|
0.19
|
1993-03-12
|
1992-12-01
|
0.19
|
1992-12-14
|
1992-08-31
|
0.19
|
1992-09-14
|
1992-05-29
|
0.19
|
1992-06-12
|
1992-02-28
|
0.19
|
1992-03-13
|
1991-12-02
|
0.19
|
1991-12-13
|
1991-08-29
|
0.19
|
1991-09-12
|
1991-05-30
|
0.19
|
1991-06-13
|
1991-03-04
|
0.19
|
1991-03-14
|
1990-11-28
|
0.19
|
1990-12-14
|
1990-08-28
|
0.19
|
1990-09-13
|
1990-05-29
|
0.19
|
1990-06-13
|
1990-03-05
|
0.19
|
1990-03-14
|
1989-11-28
|
0.19
|
1989-12-14
|
1989-08-24
|
0.28
|
1989-09-29
|
1989-05-29
|
0.25
|
1989-06-13
|
1989-03-03
|
0.25
|
1989-03-14
|
1988-12-05
|
0.25
|
1988-12-14
|
1988-08-28
|
0.22
|
1988-09-14
|
1988-07-04
|
0.03
|
1988-07-14
|
1988-05-26
|
0.22
|
1988-06-13
|
1988-02-29
|
0.22
|
1988-03-14
|
1987-12-14
|
0.22
|
1988-01-08
|
1987-08-27
|
0.22
|
1987-09-14
|
1987-06-01
|
0.22
|
1987-06-14
|
1987-03-02
|
0.30
|
1987-03-12
|
1986-12-15
|
0.30
|
1987-01-09
|
1986-08-26
|
0.30
|
1986-09-11
|
1986-05-21
|
0.30
|
1986-06-04
|
1986-02-28
|
0.60
|
1986-03-13
|
1985-11-29
|
0.40
|
1985-12-13
|
1985-08-27
|
0.40
|
1985-09-12
|
1985-06-07
|
0.40
|
1985-06-20
|
1985-03-01
|
0.40
|
1985-03-14
|
1984-11-29
|
0.40
|
1984-12-14
|
1984-08-30
|
0.40
|
1984-09-14
|
1984-05-31
|
0.40
|
1984-06-14
|
1984-03-01
|
0.40
|
1984-03-14
|
1984-01-27
|
0.02
|
1984-02-17
|
1983-12-27
|
0.40
|
1984-01-10
|
1983-08-29
|
0.40
|
1983-09-14
|
1983-05-27
|
0.40
|
1983-06-14
|
1983-03-03
|
0.40
|
1983-03-14
|
1983-01-27
|
0.02
|
1983-02-18
|
1982-12-28
|
0.40
|
1983-01-10
|
1982-08-30
|
0.40
|
1982-09-14
|
1982-05-28
|
0.40
|
1982-06-14
|
1982-02-26
|
0.40
|
1982-03-12
|
1982-01-28
|
0.02
|
1982-02-19
|
1981-12-28
|
0.10
|
1982-01-11
|
1981-08-28
|
0.40
|
1981-09-14
|
1981-05-27
|
0.40
|
1981-06-12
|
1981-02-27
|
0.40
|
1981-03-13
|
1981-01-29
|
0.02
|
1981-02-20
|
1980-12-01
|
0.40
|
1980-12-15
|
1980-08-29
|
0.40
|
1980-09-15
|
1980-05-28
|
0.40
|
1980-06-13
|
1980-02-27
|
0.40
|
1980-03-13
|
1980-01-30
|
0.02
|
1980-02-19
|
1979-11-28
|
0.40
|
1979-12-13
|
1979-08-30
|
0.35
|
1979-09-14
|
1979-05-25
|
0.35
|
1979-06-14
|
1979-02-28
|
0.35
|
1979-03-13
|
1979-01-28
|
0.02
|
1979-02-15
|
1978-11-23
|
0.35
|
1978-12-12
|
1978-08-30
|
0.35
|
1978-09-12
|
1978-05-23
|
0.35
|
1978-06-12
|
1978-03-01
|
0.35
|
1978-03-13
|
1978-01-26
|
0.02
|
1978-02-16
|
1977-11-27
|
0.35
|
1977-12-12
|
1977-08-28
|
0.35
|
1977-09-12
|
1977-05-26
|
0.30
|
1977-06-13
|
1977-03-06
|
0.30
|
1977-03-20
|
